All work in my section began in February 2017, so there are no CCR-based accomplishments to report yet. Nonetheless, we have generated a large panel of novel IFITM3 mutants to aid in our study. Furthermore, we have developed systems using MLV-based vectors and adapted a pseudotyping procedure to study how various retroviral glycoproteins affect viral susceptibility to IFITM-mediated antiviral activities. Our data thus far suggest that IFITM3 exhibits great breadth with regard to its ability to inhibit retroviral particle infectivity. These findings suggest that these antiviral proteins may impose serious barriers to multiple mammalian retroviruses of medical importance in different species.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011779-01
Application #
9556743
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code